Alerts
Want to monitor CPRX?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor CPRXWant to monitor CPRX?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor CPRXcatalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.